세계의 연결형 약물 전달 장치 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 제품 유형별, 투여 경로별, 용도별, 지역별, 경쟁별(2020-2030년)
Connected Drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type, By Route of Administration, By Application, By Region & Competition, 2020-2030F
상품코드:1785351
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 연결형 약물 전달 장치 시장 규모는 2024년에 64억 5,000만 달러로 평가되었고 2030년에는 151억 5,000만 달러에 이를 것으로 예측되며, CAGR은 15.25%를 나타낼 전망입니다.
세계의 연결형 약물 전달 장치 시장은 첨단 디지털 기술의 통합, 의료 서비스 제공 모델의 변화, 개인 맞춤형 결과 중심 치료에 대한 강조의 증가에 따라 큰 변화를 겪고 있습니다. 내장 센서, 블루투스 연결, 동반 모바일 앱 및 클라우드 기반 분석 기능을 갖춘 이러한 차세대 약물 전달 시스템은 특히 만성 질환 관리에 있어 약물 준수율을 높이고 실행 가능한 건강 인사이트를 제공하며 장기적인 치료 결과를 개선하기 위해 특별히 설계되었습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
64억 5,000만 달러
시장 규모 : 2030년
151억 5,000만 달러
CAGR(2025-2030년)
15.25%
급성장 부문
비경구
최대 시장
북미
의료 혁신, 디지털 전환, 의약품 발전의 교차점에 위치한 이 시장은 강력한 성장세를 보이고 있습니다. 바이오제약 기업, 의료기기 업체, 보험사, 의료 제공자 등 생태계 내 모든 이해관계자들은 원격 모니터링을 지원하고 복약 준수 추적을 자동화하며 실시간 환자 참여를 가능하게 하는 연결형 치료 플랫폼에 적극적으로 투자하고 있습니다. 규제 프레임워크가 성숙하고 디지털 헬스케어 보상 체계가 구조화됨에 따라, 특히 만성 질환 부담이 증가하고 디지털 인프라가 발전하는 지역에서 시장 규모가 급속히 확대될 것으로 예상됩니다. 연결형 약물 전달의 미래는 더 이상 틈새 시장이 아닙니다. 정밀 의학 및 분산형 의료 서비스의 미래에 전략적 축으로 부상하고 있습니다.
시장 성장 촉진요인
장기적인 약물 치료가 필요한 만성 질환의 유병률 증가
주요 시장 과제
높은 기기 비용 및 제한적인 보험 적용
주요 시장 동향
연결형 기기에 인공 지능(AI) 및 고급 분석 통합
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 연결형 약물 전달 장치 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
제품 유형별(독립형 컴포넌트 및 소프트웨어, 통합 디바이스)
투여경로(비경구, 흡입)
용도별(천식, COPD, 당뇨, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 연결형 약물 전달 장치 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 연결형 약물 전달 장치 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 연결형 약물 전달 장치 시장 전망
시장 규모와 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 연결형 약물 전달 장치 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 연결형 약물 전달 장치 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
합병과 인수
제13장 세계의 연결형 약물 전달 장치 시장 : SWOT 분석
제14장 경쟁 구도
Teva Pharmaceutical Industries Ltd.
Novo Nordisk A/S
Phillips Medisize
Medtronic Plc.
Adherium Limited
Tandem Diabetes Care, Inc.
Biocorp Life Sciences Pvt. Ltd
Resmed Corp
Ypsomed AG
AptarGroup, Inc.
제15장 전략적 제안
제16장 기업 소개와 면책사항
HBR
영문 목차
영문목차
Global Connected Drug Delivery Devices market was valued at USD 6.45 Billion in 2024 and is expected to reach USD 15.15 Billion by 2030 with a CAGR of 15.25%. The Global Connected Drug Delivery Devices Market is undergoing a significant evolution, shaped by the integration of advanced digital technologies, shifting healthcare delivery models, and the rising emphasis on personalized, outcomes-driven care. These next-generation drug delivery systems equipped with embedded sensors, Bluetooth connectivity, companion mobile apps, and cloud-based analytics are purpose-built to enhance medication adherence, deliver actionable health insights, and improve long-term treatment outcomes, particularly for chronic disease management.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 6.45 Billion
Market Size 2030
USD 15.15 Billion
CAGR 2025-2030
15.25%
Fastest Growing Segment
Parenteral
Largest Market
North America
Positioned at the nexus of healthcare innovation, digital transformation, and pharmaceutical advancement, this market is gaining strong momentum. Stakeholders across the ecosystem including biopharma companies, medtech firms, payers, and providers are actively investing in connected therapeutic platforms that support remote monitoring, automate adherence tracking, and enable real-time patient engagement. As regulatory frameworks mature and digital health reimbursement becomes more structured, the market is set to scale rapidly, especially in regions with growing chronic disease burdens and increasing digital infrastructure. The connected drug delivery landscape is no longer a niche it's emerging as a strategic pillar in the future of precision medicine and decentralized care delivery.
Key Market Drivers
Rising Prevalence of Chronic Diseases Requiring Long-Term Medication
The escalating global burden of chronic diseases is a primary catalyst fueling the growth of the Global Connected Drug Delivery Devices Market. Chronic diseases such as cardiovascular disorders, cancer, diabetes, and chronic respiratory illnesses now represent the primary drivers of mortality and long-term disability worldwide. These conditions account for approximately 75% of all global deaths, underscoring their disproportionate impact on both public health and economic productivity. Chronic diseases account for nearly three-quarters of global deaths and continue to rise due to aging populations, sedentary lifestyles, urbanization, and poor dietary habits.
Over 537 million adults are currently living with diabetes, a number expected to exceed 783 million by 2045. According to the Global Initiative for Asthma (GINA), asthma remains one of the most widespread chronic non-communicable diseases, impacting more than 260 million individuals globally. It is a major contributor to global morbidity and is linked to over 450,000 deaths annually. The high incidence and mortality associated with asthma reflect a persistent gap in disease control, adherence, and access to effective management tools particularly in underserved regions. This highlights a growing market opportunity for connected respiratory drug delivery solutions that can improve treatment precision, monitor patient adherence in real time, and reduce preventable asthma-related complications. These diseases often require daily or weekly medication regimens involving injectables, inhalers, or complex drug delivery protocols. This rapidly growing patient pool directly increases demand for connected devices that ensure accurate dosing, adherence tracking, and ongoing patient support.
Medication non-adherence is a major concern in chronic disease management, leading to worsening health outcomes, increased hospitalizations, and higher healthcare costs. Research consistently indicates that 40% to 60% of patients managing chronic conditions exhibit poor medication adherence, frequently skipping doses, mismanaging dosage schedules, or discontinuing treatment prematurely. Connected drug delivery devices help solve this challenge by: Providing automated reminders and alerts through mobile apps. Tracking real-time usage and sending adherence data to healthcare providers. Enabling patient engagement through visual feedback, usage history, and digital coaching. By improving adherence, these devices not only enhance clinical outcomes but also align with the priorities of healthcare payers and providers who are focused on value-based care delivery. Patients with chronic conditions often require long-term, consistent drug administration that can be managed at home without the need for frequent clinic visits. Connected drug delivery devices support this transition by enabling: Self-injection or inhalation with minimal training, even for biologics and specialty medications. Real-time feedback to ensure correct usage, minimizing the risk of administration errors. Remote data sharing with physicians, allowing for continuous therapy optimization and proactive intervention. This functionality is especially crucial for diseases like rheumatoid arthritis, multiple sclerosis, and hormone disorders, where biologics and specialty injectables are becoming the standard of care.
Key Market Challenges
High Cost of Devices and Limited Reimbursement Support
One of the most significant barriers to market expansion is the high upfront cost associated with connected drug delivery devices, especially compared to traditional drug administration methods. These devices often incorporate advanced features such as Bluetooth connectivity, integrated sensors, and cloud-based data transmission all of which increase production costs.
For healthcare providers and payers, especially in price-sensitive markets, justifying the added cost becomes challenging without a clear and quantifiable return on investment (ROI). Reimbursement frameworks remain fragmented and inconsistent across regions. In many countries, connected devices are not fully covered under public or private insurance plans, limiting patient accessibility particularly in low- and middle-income economies. Additionally, the cost of accompanying digital infrastructure (such as mobile apps, cloud platforms, and device integration with EHRs) can further complicate adoption. Until reimbursement models evolve to recognize the long-term cost savings of improved adherence and reduced hospitalizations, affordability will continue to be a limiting factor.
Key Market Trends
Integration of Artificial Intelligence (AI) and Advanced Analytics into Connected Devices
One of the most significant trends shaping the future of connected drug delivery devices is the integration of AI and real-time analytics. Modern devices are evolving from passive tracking tools into intelligent therapeutic systems capable of learning from user data and dynamically optimizing treatment regimens.
Predictive dosing algorithms can now analyze historical adherence data, biometrics (e.g., blood glucose levels), and behavioral trends to fine-tune dosage recommendations in real time. AI-driven insights allow early identification of non-compliance, adverse events, or therapy deviations, which helps healthcare providers intervene proactively. This trend is particularly impactful in chronic disease management such as diabetes and asthma, where continuous optimization of therapy enhances patient outcomes while reducing hospitalization costs. Pharmaceutical companies are increasingly partnering with digital health firms to develop smart therapeutics, combining connected devices with data-driven platforms, creating a seamless patient-provider feedback loop.
Key Market Players
Teva Pharmaceutical Industries Ltd.
Novo Nordisk A/S
Phillips Medisize
Medtronic Plc.
Adherium Limited
Tandem Diabetes Care, Inc.
Biocorp Life Sciences Pvt. Ltd
Resmed Corp
Ypsomed AG
AptarGroup, Inc
Report Scope:
In this report, the Global Connected Drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Connected Drug Delivery Devices Market, By Product Type:
Standalone Components & Software
Integrated Devices
Connected Drug Delivery Devices Market, By Route of Administration:
Parenteral
Inhalational
Connected Drug Delivery Devices Market, By Application:
Asthma
COPD
Diabetes Management
Others
Connected Drug Delivery Devices Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Connected Drug Delivery Devices Market.
Available Customizations:
Global Connected Drug Delivery Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Connected Drug Delivery Devices Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Standalone Components & Software, Integrated Devices)
5.2.2. By Route of Administration (Parenteral, Inhalational)
5.2.3. By Application (Asthma, COPD, Diabetes Management, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Connected Drug Delivery Devices Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Route of Administration
6.2.3. By Application
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Connected Drug Delivery Devices Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Application
6.3.2. Canada Connected Drug Delivery Devices Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Application
6.3.3. Mexico Connected Drug Delivery Devices Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Application
7. Europe Connected Drug Delivery Devices Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Route of Administration
7.2.3. By Application
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Connected Drug Delivery Devices Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Application
7.3.2. United Kingdom Connected Drug Delivery Devices Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Application
7.3.3. Italy Connected Drug Delivery Devices Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Application
7.3.4. France Connected Drug Delivery Devices Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Application
7.3.5. Spain Connected Drug Delivery Devices Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Application
8. Asia-Pacific Connected Drug Delivery Devices Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Route of Administration
8.2.3. By Application
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Connected Drug Delivery Devices Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Application
8.3.2. India Connected Drug Delivery Devices Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Application
8.3.3. Japan Connected Drug Delivery Devices Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Application
8.3.4. South Korea Connected Drug Delivery Devices Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Application
8.3.5. Australia Connected Drug Delivery Devices Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Application
9. South America Connected Drug Delivery Devices Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Route of Administration
9.2.3. By Application
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Connected Drug Delivery Devices Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Application
9.3.2. Argentina Connected Drug Delivery Devices Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Application
9.3.3. Colombia Connected Drug Delivery Devices Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Application
10. Middle East and Africa Connected Drug Delivery Devices Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Route of Administration
10.2.3. By Application
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Connected Drug Delivery Devices Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Application
10.3.2. Saudi Arabia Connected Drug Delivery Devices Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Application
10.3.3. UAE Connected Drug Delivery Devices Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Connected Drug Delivery Devices Market: SWOT Analysis
